Insight Molecular Diagnostics (IMDX) Prepaid Assets (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 11 years of Prepaid Assets data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Prepaid Assets fell 15.14% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 15.14% YoY) and the FY2025 annual result came in at $1.4 million, up 72.96% from the prior year.
• Prepaid Assets eased to $1.0 million in Q1 2026 per IMDX's latest filing, from $1.4 million in the prior quarter.
• The five-year high for Prepaid Assets was $2.2 million in Q3 2022, with the low at $595000.0 in Q2 2024.
• Average Prepaid Assets over 5 years is $1.1 million, with a median of $1.0 million recorded in 2026.
• Year-over-year, Prepaid Assets jumped 18837.5% in 2022 and slumped 69.09% in 2023.
• Insight Molecular Diagnostics' Prepaid Assets stood at $977000.0 in 2022, then tumbled by 34.19% to $643000.0 in 2023, then grew by 27.68% to $821000.0 in 2024, then jumped by 72.96% to $1.4 million in 2025, then declined by 26.2% to $1.0 million in 2026.
• Business Quant data shows IMDX's Prepaid Assets at $1.0 million in Q1 2026, $1.4 million in Q4 2025, and $1.2 million in Q3 2025.